EP1781279A2 - Preparation pour la prophylaxie et la therapie d'etats de stress et de troubles fonctionnels et organiques du systeme nerveux et du metabolisme - Google Patents

Preparation pour la prophylaxie et la therapie d'etats de stress et de troubles fonctionnels et organiques du systeme nerveux et du metabolisme

Info

Publication number
EP1781279A2
EP1781279A2 EP05761475A EP05761475A EP1781279A2 EP 1781279 A2 EP1781279 A2 EP 1781279A2 EP 05761475 A EP05761475 A EP 05761475A EP 05761475 A EP05761475 A EP 05761475A EP 1781279 A2 EP1781279 A2 EP 1781279A2
Authority
EP
European Patent Office
Prior art keywords
glycine
preparation
disorders
prophylaxis
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05761475A
Other languages
German (de)
English (en)
Inventor
Egon Tech
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE202004009180U external-priority patent/DE202004009180U1/de
Priority claimed from DE202004009689U external-priority patent/DE202004009689U1/de
Application filed by Individual filed Critical Individual
Publication of EP1781279A2 publication Critical patent/EP1781279A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations

Definitions

  • the invention relates to a glycine-containing preparation for the prophylaxis and therapy of stressful conditions, functional and organic disorders of the nervous system and metabolism, and for external use in sun allergy sufferers and against sunburn, in particular in the case of inflammatory reactions of the skin by UV-A, UV-B - and UV-C rays from the sun or artificial light sources and stressors, which accelerate the aging process of the cell / cell systems and for external and internal use to minimize stress in people who are particularly exposed to psycho-emotional stress (work, work, school, Studies, sports, competitive sports, premenstrual-menstrual-postmenstrual stress, PMSD), to increase libido, to increase erection (in the case of stress-related deficits), for more balance in older age, to weaken hyperactivity in adults and children, to increase the body's defenses against pollutants and environmental toxins, electrical smog etc. as well as for the prevention and therapy support of addictions.
  • psycho-emotional stress work, work, school, Studies, sports,
  • the recipe can also be used to minimize stress in animals (pets and exotic animals).
  • Areas of application of the invention are medicine and pharmacy.
  • Glycine has the empirical formula H 2 N-CH 2 -COOH and is the simplest (non-essential) amino acid. Glycine is formed from serine (cleavage of activated formaldehyde by serine hydroxymethyltransferase), from L-threonine (acetaldehyde cleavage by threonine aldolase) or from glyoxylate (by transamination).
  • glycine in the context of synaptic signal transmission is the inhibitory effect on the glycine receptors for regulating intrinsic chloride channels in the spinal cord and cortex.
  • Ion channels are membrane proteins that run through the cell membrane from the inside out.
  • the membrane itself is a very efficient diffusion barrier for ions.
  • the hydrophobic inner area of the membrane prevents the access of ions and thus enables the maintenance of ion gradients between the cytoplasm and the extracellular space.
  • Ion channels have a narrow pore through which ions can get out of or into the cell.
  • the so-called ligand-controlled ion channels are at the center of signal transmission at chemical synapses.
  • the ligands are called neurotransmitters, which bind to assigned receptors on the surface of a target cell as chemical messengers.
  • trans-membrane segments consist of many hydrophobic and few hydrophilic amino acid residues, with polar and charged amino acids predominating outside the membrane.
  • the pore is opened for the passage of a particular ion at the moment when a ligand docks to a specialized protein domain (ligand binding site), which leads to a change in the conformity of the pore.
  • the ligand binding sites are on the outside of the cell.
  • the receptors for the neurotransmitters acetylcholine, glutamate, glycine, ⁇ -amino butyric acid and serotonin are positioned here. All of these receptors have a homologous structure and are combined into a superfamily. The best studied representative of this group is the nicotinic acetylcholine receptor, which is mostly used as an explanatory model.
  • the neurotransmitters mentioned have ion selectivity, ie when the transmitter is docked to the receptor, the ion channel only becomes continuous for certain ions.
  • acetylcholine opens the passage of sodium, potassium and calcium ions on the motor end plate of the muscles or the autonomic ganglia and leads to an activation of the target cells (excitatory effect, depolarization of the membrane).
  • the neurotransmitter glycine regulates the passage of chloride ions and hydrogen carbonate ions, especially in the nerve cells of the spinal cord and the brain stem, and has an inhibitory effect on the affected nerve cell (inhibitory effect, hyperpolarization).
  • Channels that are controlled by cytoplasmic ligands have binding sites for cellular messenger substances on the inside of the membrane (controlled by guanine adenosine phosphate).
  • strychnine-sensitive glycine receptor (specific antagonist strychnine) as a ligand-controlled chloride channel of the postsynaptic membrane is an important mediator of synaptic inhibition in the central nervous system. Glycine is primarily involved in the neuronal regulation of muscle tone through the centers in the spinal cord and brain stem.
  • glycinergic inhibition also contributes to the development of the breathing rhythm in the respiratory centers of the brain stem.
  • Forming a control loop leads to dysregulation of the skeletal muscles with the formation of painful cramps.
  • chloride channels which can also be hereditary, are also known as ion channel diseases (channel pathathies). These show up in hypertensive movement disorders.
  • channel pathathies ion channel diseases
  • agonists on the glycine receptors are the amino acids ß-alanine and
  • Emotional stress is a complex, holistic function.
  • a stressor is the stress-triggering stimulus that can come from both the exogenous and the endogenous milieu.
  • Emotional stress can manifest itself in two forms:
  • Eustress promotes the health, motivation to perform and adaptability of the individual.
  • the relationship between eustress and performance is not linear, but is subject to a bell-shaped curve (Yerkes-Dodson's law).
  • Disstress is a promoter for 80 percent of all diseases including cancer, allergies, AIDS, cardiovascular diseases and mental disorders. Disstress is the No. 1 disruptive factor for quality of life, performance and health in many countries (e.g. USA, Japan, Germany, Switzerland).
  • Most people and even children are stressed, mentally and physically tense, tense or overstretched and also aggressive. As a result, they cannot fall asleep, suffer from reduced performance and make mistakes.
  • Mental self-talk, brooding, negative thinking also distress and prevent involuntary relaxation.
  • special technical warning systems i. H. a distress warning device and immediately accessible biofeedback systems that can objectively control relaxation and also systems that indicate or signal that a break is necessary every 90 - 100 minutes.
  • the object of the present invention was to develop substances or mixtures of substances which can be used for
  • prophylaxis and therapy of stressful conditions a) prophylaxis and therapy of stressful conditions, b) prophylaxis and therapy of functional and organic disorders of the nervous system, c) prophylaxis and therapy of metabolic disorders, d) binding of toxic substances, e) physiological activation of inhibitory processes in the CNS, f) prophylaxis and therapy of mental disorders, g) prophylaxis and therapy of the syndrome of reduced ability to work and mental overload. (h) to develop substances or mixtures of substances which:
  • glycine also acts as a co-transmitter on the excitatory NMDA receptors (N-methyl-D-aspartate receptor) by promoting the opening of this ion channel induced by glutamate via a specific binding domain.
  • NMDA receptors In addition to excitatory signal transmission and the formation of the nervous system, the NMDA receptors also play a special role in diseases of the CNS. The apoplexy and other central nervous disorders caused by neurotoxic cell deaths are the result of the excessive activation of NMDA receptors. Excessive arousal and other mental illnesses should also be classified here.
  • the preparation according to the invention is a regulator of the metabolism, it normalizes processes of arousal and inhibition in the CNS, has an anti-stress effect and increases the intellectual ability to work.
  • the preparation can be administered to healthy children of one year of age, adolescents and adults to increase their intellectual ability to work, in stressful situations, with psycho-emotional tension (exams, conflicts, etc.).
  • an anti-stress agent and nootropic agent it can affect children older than 1 year, adolescents (including those with changes in behavior) and adults
  • Various functional and organic diseases of the nervous system neuroneuroses, neurotic states and vegetative dystonia, with functional and organic consequences of brain traumas, with various forms of encephalopathies, including alcohol pathogenesis), which are of increased excitability, emotional lability, restriction of intellectual ability to work and sleep disorders be accompanied, applied.
  • Glycine is preferably administered orally (gel), intranasally (as a sol-gel formulation) or vaginally (gel), particularly preferably sublingually (placed under the tongue) in tablet form / gel form of 0.1 g each.
  • the preparation should be used in the case of memory impairment, restricted attention and concentration, restricted intellectual ability to work, as well as child and adolescent inhibition of intellectual ability to work and changes in behavior in doses of 2 - 3 x 1 tablet / Day for a period of 14-30 days.
  • the daily dosage is 0.3 g.
  • the preparation is used in doses of 2 - 3 x 1 tablet per day for a period of 14-30 days.
  • the dosage should be as follows:
  • glycine For sleep disorders, glycine should be given 20 minutes before bedtime or immediately before in a dose of Vi tablet (depending on age). In narcology, glycine is dosed as follows, as an agent that increases intellectual ability to work, and as an agent against psychoemotional tension during remission of the encephalopathological symptoms and in the case of organic changes in the central and peripheral nervous system:
  • the preparation does not increase the effects of sleeping pills and alcoholic beverages.
  • Glycine Glycocoll
  • Glycine inhibition mediator which interacts with glycinergic receptors of the spinal cord and the brain and thereby contributes to the normalization of the balance between excitatory and inhibitory neurotransmitter systems.
  • Glycine also has the ability to bind (neutralize: phenols, aldehydes, barbiturates, etc.) various endogenous toxic substances, which makes it possible to use glycine as a therapeutic and prophylactic in areas with unfavorable ecology (environmental pollution).
  • glycine In its mechanism of action and pharmacological effect, glycine has no analogs (combines anti-stress, stress protection and nootropic effects). The effect is achieved through physiological activation of inhibitory processes in the CNS. Glycine has a quick pharmacological effect. (The preparation works within 5 - 10 minutes and does not require replacement therapy.) Glycine is administered in 10 times smaller doses than other nootropic preparations. Contraindications and undesirable side effects have not been demonstrated. An overdose of the preparation is not possible. In contrast to tranquilizers, no symptoms of addiction and no withdrawal symptoms are observed when glycine is taken permanently. Glycine can be taken at any age ("family product").
  • Diseases of the nervous system for example: disorders of the brain circulation (circulatory disorders of the brain), residual symptoms of disorders of the brain circulation (circulatory disorders of the brain), ischemic insults, residual symptoms of ischemic insults, metabolic dystrophic disorders of the nervous system, traumatic brain injuries, cerebral pelvic insufficiency, cerebral pelvic insufficiency, residual symptoms of cerebral pelvic insufficiency.
  • Metabolic disorders e.g. in children in the period of intensive growth, with signs of aging.
  • Mental disorders e.g. abstinence symptoms, alcoholism, insomnia, disorders in the perception of information, coma, Disorders of intellectual functions, dementia, lack of concentration, memory disorders, aggressiveness, behavioral disorders (arousal or inhibition), obsessive-compulsive disorder, obsessive-compulsive disorder, emotional tension, pseudomelancholia in old age, irritability, depressive states, inner restlessness, emotional lability, neurosthenia, alcohol psychosis , Encephalopathies, juvenile and other behavioral disorders.
  • Intoxications e.g. Benzoline intoxication, arsenic intoxication, drug intoxication, hypnotic and tranquilizer intoxication.
  • gel formers with the same mechanism of action as those described below can be used to produce the preparation according to the invention, so also e.g. Carbopol 974 P and PNC 400 (basic gel formulation type C).
  • the zeolite described below is replaced by Si0 2
  • Nanoparticles especially Köstrosol, replaced. Both variants are possible.
  • the dose of the glycine content can be increased to at least 10 times the stated values.
  • Veterinary use The use can be made as in the human area, the dose for small animals is the same as for the named ones.
  • Technological preparations are necessary for administration via the feed, such as microencapsulation, gelling, and coating (coating with high-molecular sugars, starch or microcellulose), which release the active substances in the small intestine.
  • a gel preparation has proven to be a particularly effective form of application which, when applied to the mucous membranes (oral, nasal and vaginal mucosa, rectum), releases the active ingredient glycine in portions for absorption.
  • an initial and depot dose can be applied.
  • the basis of the present invention is formed by gels with high ion exchange capacity, high penetration into the various skin layers and high adhesion to the skin and to the mucous membrane.
  • the essence of the invention is a constantly repeating basic formulation which can be mixed with other components.
  • Sorbic acid and glycine are dissolved in hot water. Carbopol is stirred in until homogeneous. It is then neutralized with NaOH (pH 5.0-5.5). Then the solution of Kollidon and water is stirred in homogeneously.
  • intranasal application also as inhalation
  • This form of application ensures a quick onset of action.
  • the effect occurs within approx. 10 seconds and lasts approx. 4 hours.
  • the formulation can be replenished at any time (e.g. in the form of a nasal spray).
  • An overdose is not possible so self-medication is absolutely harmless and harmless.
  • the onset of effects is noticeable with a shine in the eyes (approx. 10 seconds after administration, sometimes faster).
  • intranasal application also as inhalation
  • applications by os and / or sublingually can also be considered.
  • the recipe is e.g. Administered microencapsulated and can be used for a wide range of indications (Crohn's disease, nervous stomach, stage fright, etc.).
  • Packaging e.g. 3ml in spray bottle or 20ml in tube with nose adapter
  • Another application option is to apply the recipe with the help of a roller (e.g. with 7ml content) to relax and minimize stress, for example around the eye area, with a simultaneous, immediately refreshing effect (tired eye effect after too little sleep or disco, etc.) and instantly tightening effect Eye area etc.
  • This area also includes use as a lip gloss with stress-minimizing properties and, at the same time, a circulation-promoting effect for larger and fuller lips.
  • Another application is as a cosmetic series for the intimate area of women, with mucous membrane contact and a quick effect (stimulating libido) or as a surface coating in tampon manufacture (for better well-being during menstruation).
  • the recipe is also used to minimize stress in domestic and domestic animals and exotic animals. Examples include cat, dog, horse, camel, parrot, parakeet, hamster, rabbit.
  • animals can take place in the same formulation and dosage.
  • animals can take place in the same formulation and dosage.
  • animals can take place in the same formulation and dosage.
  • animals can take place in the same formulation and dosage.
  • animals can take place in the same formulation and dosage.
  • animals can take place in the same formulation and dosage.
  • animals can take place in the same formulation and dosage.
  • animals can take place in the same formulation and dosage.
  • animals can take place in the same formulation and dosage.
  • small animals and ornamental birds e.g. 0.18 ml per cat or small dog, larger dogs receive 3-4 times the dose).
  • These plant components are used as a replacement for the components of animal cell lines and their production with comparable modes of action / indications for animal and mammalian cells, in particular by using their components with a molecular weight of 0-10 kDa and greater than 10 kDa and greater than 100 kDa.
  • UVA / B / C and other artificial light sources are illustrated by the following description.
  • the leaves of the freshly harvested aloe are briefly exposed to microwave radiation, which does not lead to the destruction of the cell structures, but only results in substances of the cell membrane as an extraordinary stressor for the formation and release of immunologically relevant substances.
  • These are cleaned, filtered and applied in the desired fractions (0-10 kDa, 10 -100 kDa and larger), depending on the indication, for external and internal use, the active properties corresponding to those of extracted mammalian cell extracts.
  • the similar components can be After shock freezing at -20 ° C for 30 minutes, achieve the freshly harvested leaves and the extraction, filter the leaf juice / gel obtained in this way, or briefly (10 min.) irradiate the freshly pressed aloe juice / gel with UVC light.
  • the extraordinary stress creates desired substances / mixtures of substances, which have excellent immunological and regulatory properties and are very similar, perhaps identical, to the mechanisms of action of those obtained from animal cell lines.
  • the indication is analogous to the known methods for obtaining components from 0-10 kDa and greater than 10 kDa with a similar objective, indications and ingredients, in particular the components of all fractions of similarly effective substances that arise from shear forces during ultracentrification.
  • the invention also encompasses the following method for energizing silicon nanoparticles or zeolites or other mineral substances / substance mixtures which have been put into use for the optimization of the control processes of plant, animal and mammalian cells / cell systems / organs, organ systems, organisms ,
  • the method is suitable for use in plant cells via the leaf, as well as in the microclimate in the root and capillary area, animal cells for all external and internal applications, mammalian cells for all external and internal applications, in particular as adjuvants in cosmetics and medicine which, for example Minerals, zeolites, bentonites etc. have been used as an allergy-free medium in products for the skin, etc., and as preferred nanoparticles for use on animal and mammalian cells.
  • the particles used were exposed to different doses / pulses of microwaves, which leads to changes in the crystal lattice and to the recording of information about the microwaves, which can vary depending on the destination and the indication.
  • a special Köstrosol with a particle diameter of 7 nanometers has been used especially for application over the skin / mucous membrane and is able to loosely bind substances with a similar particle size and as a transporter for the preferred substances as well as in the mentioned molecular weights 0- 10 kDa and greater than 10 kDa, as well as the filtered supernatants and extracted membrane components, in particular obtained from Aloe barbadensis miller using the described method, to the target sites on or in the organism.
  • the applied vibration is transmitted and the immunologically desired particles are transported.
  • the indications include all inflammatory, allergic processes that are caused by unusual stressors and are the subject of the invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Birds (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne une préparation pour la prophylaxie et la thérapie d'états de stress et de troubles fonctionnels et organiques du système nerveux et du métabolisme, pour l'application dans le cas d'allergies dues au soleil, de coups de soleil, comme régénérateur de cellules/systèmes cellulaires endommagés, et pour le bien-être des êtres humains ou animaux. L'invention concerne en outre un procédé d'isolement des constituants cellulaires de l'Aloe barbadensis miller, pour la production de micro- et nanoparticules énergisantes/magnétisantes, ainsi que l'utilisation de constituants cellulaires. Les moyens connus jusqu'à présent, utilisables dans le cas des indications précitées sont d'une fabrication coûteuse et n'offrent que des propriétés insuffisantes. Des préparations contenant de la glycine, en particulier en formulation gel, sont faciles à produire et sont, de façon surprenante, avantageuses dans les applications les plus diverses. Les préparations conviennent, par suite des propriétés remarquables de la glycine, pour les applications externes et/ou internes, et offrent une prophylaxie efficace et des possibilités de traitement de différentes zones du corps affectées ou d'amélioration de l'état perçu.
EP05761475A 2004-06-11 2005-06-10 Preparation pour la prophylaxie et la therapie d'etats de stress et de troubles fonctionnels et organiques du systeme nerveux et du metabolisme Withdrawn EP1781279A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE202004009180U DE202004009180U1 (de) 2004-06-11 2004-06-11 Rezeptur für die äußere Anwendung bei Sonnenallergikern und gegen Sonnenbrand sowie für die äußere und innere Anwendung zur Streßminderung und Steigerung des Wohlbefindens bei Tier und Mensch
DE202004009689U DE202004009689U1 (de) 2004-06-18 2004-06-18 Präparat zur Prophylaxe und Therapie von Stresszuständen sowie von funktionellen und organischen Störungen des Nervensystems und des Stoffwechsels
PCT/DE2005/001073 WO2005120487A2 (fr) 2004-06-11 2005-06-10 Preparation pour la prophylaxie et la therapie d'etats de stress et de troubles fonctionnels et organiques du systeme nerveux et du metabolisme

Publications (1)

Publication Number Publication Date
EP1781279A2 true EP1781279A2 (fr) 2007-05-09

Family

ID=35094203

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05761475A Withdrawn EP1781279A2 (fr) 2004-06-11 2005-06-10 Preparation pour la prophylaxie et la therapie d'etats de stress et de troubles fonctionnels et organiques du systeme nerveux et du metabolisme

Country Status (3)

Country Link
US (1) US20090017047A1 (fr)
EP (1) EP1781279A2 (fr)
WO (1) WO2005120487A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3701945A1 (fr) * 2004-08-09 2020-09-02 Enrique Melendez Hevia Composition de glycine pour la prévention et/ou le traitement du cancer chez un humain nécessitant une promotion de la synthèse du collagène
DE102006051941A1 (de) 2006-01-24 2007-07-26 Egon Tech Multifunktionales Wirkstoffgemisch
DE202007007542U1 (de) * 2007-05-26 2007-10-04 Tech, Egon Aminosäure-Mineral-Peptid-Komplex, insbesondere quantenmechanisch modifiziert, als Arzneimittel zur Behandlung von Demenzerkrankungen
DE202010010638U1 (de) 2010-06-28 2010-10-21 Tech, Egon Nano-Hydrogele für die therapeutische und nichttherapeutische Behandlung, insbesondere zur Therapie von Stresszuständen und Regeneration
EP4061387A1 (fr) * 2019-11-18 2022-09-28 Société des Produits Nestlé S.A. Compositions et procédés d'amélioration du glutathion pour une utilisation dans la santé cérébrale
JP2026507865A (ja) * 2023-03-10 2026-03-06 ブライトシード・インコーポレイテッド ストレス調節用組成物および方法ならびにその使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311804D0 (en) * 1983-04-29 1983-06-02 Merrell Toraude & Co Treatment of seizure disorders and pharmaceutical compositions
GB8401965D0 (en) * 1984-01-25 1984-02-29 Beecham Group Plc Composition
US5051258A (en) * 1989-10-13 1991-09-24 Natrol, Inc. Dietary supplement for children
GB9512100D0 (en) * 1995-06-14 1995-08-09 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
PT871440E (pt) * 1995-12-07 2006-07-31 Daniel C Javitt Tratamento de sintomas negativos e cognitivos de esquizofrenia com antagonistas da captacao de glicina
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US7544348B2 (en) * 2001-02-15 2009-06-09 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
DE10113334A1 (de) * 2001-03-20 2002-09-26 Cognis Deutschland Gmbh Quartäre Tenside
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
DE10243233A1 (de) * 2002-09-17 2004-04-15 Phenion Gmbh & Co. Kg Verwendung von Substanzen zum Schutz der Haut

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005120487A2 *

Also Published As

Publication number Publication date
WO2005120487A3 (fr) 2006-07-20
US20090017047A1 (en) 2009-01-15
WO2005120487A2 (fr) 2005-12-22

Similar Documents

Publication Publication Date Title
DE69930375T2 (de) Xylitolzusammensetzungen zur behandlung der oberen atmungsorgane
DE10262193B4 (de) Kosmetische Verwendung eines Wirkstoffs zur Stimulierung der humanen beta-Defensine vom Typ 2 und/oder Typ 3, Verwendung eines solchen Wirkstoffs zur Herstellung einer pharmazeutischen Zusammensetzung, die einen solchen Wirkstoff enthält und Verwendung eines solchen Wirkstoffs auf dem Gebiet der Geweberekonstruktion
DE3876877T2 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
CH701268B1 (de) Homöopathische Rezeptur.
DE69731968T2 (de) Isovaleramid zur behandlung von schüttelkrämpfen, epilepsie, kopfschmerzen und spastischer lähmung
Tamano et al. Preventive effect of theanine intake on stress-induced impairments of hippocamapal long-term potentiation and recognition memory
DE112011102397T5 (de) Pharmazeutische Kombinationszusammensetzungen und Verfahren zur Behandlung von Schwindel, Kinetose und vegetativ-vaskulärer Dystonie
DE69209414T2 (de) Hirnaktivitätfördernde Zubereitungen
WO2009065395A2 (fr) Nouvelle utilisation d'acide(s) gras oméga-3
WO2005120487A2 (fr) Preparation pour la prophylaxie et la therapie d'etats de stress et de troubles fonctionnels et organiques du systeme nerveux et du metabolisme
CH677319A5 (de) Kosmetische mittel zur gesundheits- und koerperpflege oder arzneimittel.
DE10149108A1 (de) Verwendung von Phosphatidylserin zur Behandlung des Aufmerksamkeits-Defizit-Syndroms (ADHS)
Manosso et al. Involvement of glutamatergic neurotransmission in the antidepressant-like effect of zinc in the chronic unpredictable stress model of depression
CN114712276A (zh) 一种舒缓改善肌肤状态的组合物及护肤品
DE102005027905A1 (de) Präparat zur Prophylaxe und Therapie von Stresszuständen, von funktionellen und organischen Störungen des Nervensystems und des Stoffwechsels
DE102014017455A1 (de) Kreatin enthaltendes Nahrungsergänzungsmittel zur Verbesserung des Schlafs
Schneider et al. Gamma-aminobutyric acid (GABA) and sleep: the influence of di-n-propylacetic acid on sleep in man
Van Keuren et al. Fixed-ratio discrimination training as replacement therapy in Parkinson's disease: studies in a 6-hydroxydopamine-treated rat model
DE202004009180U1 (de) Rezeptur für die äußere Anwendung bei Sonnenallergikern und gegen Sonnenbrand sowie für die äußere und innere Anwendung zur Streßminderung und Steigerung des Wohlbefindens bei Tier und Mensch
EP2918177B1 (fr) Complément alimentaire pour l'optimisation du sommeil
CN115176919A (zh) 一种可帮助宠物轻松抵抗应激的复合预混料及其应用
Tuychiyev BASIC SEDATIVES
RU2260438C2 (ru) Способ стимуляции воспроизводительной функции крупного рогатого скота
AT514349B1 (de) Alpha-alkylierte Aminosäuren (AAAAs)
DE19634537A1 (de) Histamin-Immunglobulin-Komplex zur Applikation auf einer Schleimhaut

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070316

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091201